title: [Long survival and effective treatment of unresectable gastric cancer by TS-1 based chemotherapy with a sequential combination].
abstract: We report a case of peritoneal cancer dissemination and cytological appearance of cancer cells with Type 4 gastric cancer. Treatment with unichemotherapy and combination chemotherapy with TS-1 proved successful. The patient was a 58-year-old female,who complained of abdominal pain. She was diagnosed as unresectable Type 4 gastric cancer, T 3 NxH 0 P 1 CY 1 M 0, Stage IV (cytology: Class V). Thirteen days after surgery, chemotherapy with TS-1 (80 mg/body/day, 4 weeks) at 2-week intervals in 1 course was performed. However, due to side effects with marrow restraint of grade 1, we changed to the following chemotherapy regimen: TS-1 (80 mg/body/day, 2 weeks) at 4-week intervals as 1 course (23 courses in total). After 16 courses, a partial response (PR) was noted. As additional therapy to recover tumor marker (CA19-9) after 21 courses, combination chemotherapy with TS-1 (80 mg/body/day, 2 weeks) and CDDP (25 mg/body/day, day 1, 8, 15 drip infusion) was performed as one course. This chemotherapy was then performed in 3 courses and tumor markers did not deteriorate, so we changed docetaxel (DOC) (50 mg/body/day(day 1)) to CDDP, and tumor markers returned to the normal value. No recurrence and no side effects appeared (hematological or non-hematological) during this combination chemotherapy.
authors.affiliation: The Third Dept. of Surgery, Tokyo Medical University.
authors.forename: Yasuhiro
authors.initials: Y
authors.lastname: Hibi
authors.forename: Yu
authors.initials: Y
authors.lastname: Takagi
authors.forename: Sumito
authors.initials: S
authors.lastname: Hoshino
authors.forename: Sou
authors.initials: S
authors.lastname: Katayanagi
authors.forename: Hideo
authors.initials: H
authors.lastname: Sudo
authors.forename: Takeshi
authors.initials: T
authors.lastname: Suda
authors.forename: Kazushige
authors.initials: K
authors.lastname: Ito
authors.forename: Akihiko
authors.initials: A
authors.lastname: Tsuchida
authors.forename: Tatsuya
authors.initials: T
authors.lastname: Aoki
mesh_terms: D000230:Adenocarcinoma / Q000188:drug therapy* / Q000556:secondary; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002945:Cisplatin / Q000008:administration & dosage; D000077143:Docetaxel; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D008875:Middle Aged; D010534:Peritoneal Neoplasms / Q000556:secondary; D011788:Quality of Life; D017640:Silicates / Q000008:administration & dosage*; D013274:Stomach Neoplasms / Q000188:drug therapy* / Q000473:pathology; D017741:Survivors; D043823:Taxoids / Q000008:administration & dosage; D014025:Titanium / Q000008:administration & dosage*
chemical_list: D017640:Silicates; D043823:Taxoids; C103828:titanium silicide; D000077143:Docetaxel; D014025:Titanium; D002945:Cisplatin